Current SATVI news
SATVI authors Drs. Adam Penn-Nicholson, Stanley Kimbung Mbandi, Michelle Fisher, Professors Mark Hatherill and Tom Scriba have co-authored a paper titled "Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study" appearing in the Plos Medicine journal.
University of Cape Vice Chancellor, Professor Mamokgethi Phakeng announced the South African Tuberculosis Vaccine Initiative (SATVI) as the winner of the 2018 Vice Chancellor Social Responsiveness Award during the April 2019 Health Faculty Sciences graduation.
For World TB Day 2019 (24 March 2019) the South African Tuberculosis Vaccine Initiative (SATVI) team tackled the World TB Day Three Peaks Challenge which entailed ascending up Devils Peak, Platteklip Gorge and Lions Head in one day, in a bid to raise awareness about Tuberculosis.
SATVI researchers Miguel Rodo, Professor Tom Scriba, Drs. Virginie Rozot, Elisa Nemes and Profesor Mark Hatherill have published a article titled: "A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates" appearing in the PLoS Pathogens journal.
The South African Tuberculosis Vaccine Initiative 2018 Annual Report is now available.
SATVI Authors Professors Mark Hatherill, Tom Scriba, Dr Munyaradzi Musvosvi, Humphrey Mulenga, Ashley Veldsman have co-authored a research paper titled "Toll-like receptor chaperone HSP90B1 and the immune response to Mycobacteria" appearing in the PLos One Journal.
Professor Tom Scriba and Dr Adam Penn-Nicholson have co-authored a research publication titled: "Batf2 differentially regulates tissue immunopathology in Type 1 and Type 2 diseases" appearing in the Mucosal Immunology Journal.
Professor Mark Hatherill has co-authored a journal article titled "Building capacity for advances in tuberculosis research; proceedings of the third RePORT international meeting" appearing in the Tuberculosis (Edinb) Journal.
Professor Tom Scriba has co-authored a paper titled: “Metabolite changes in blood predict the onset of tuberculosis” in the Nature Journal.
Prof Mark Hatherill has co-authored a journal article titled: "Safety and Immunogenicity of early Bacillus Calmette-Guerin (BCG) vaccination in infants who are preterm and/or have low birth weights: A systematic review and meta-analysis" appearing in the Journal of American Medical Association (JAMA).
SATVI Director Professor Mark Hatherill has co-authored a commentary titled "WHO preferred product characteristics for new vaccines against tuberculosis" appearing in The Lancet journal.
Associate Professor Tom Scriba has co authored a paper titled "Can we predict tuberculosis cure? What tools are available?" appearing in the European Respiratory Journal of the European Respiratory Society.